Founded in October 2000, Zhejiang Guobang Pharmaceutical is a core enterprise of the Guobang Pharmaceutical Group. The company is located in the Hangzhou Bay Shangyu Economic and Technological Development Zone in Shangyu District, Shaoxing, Zhejiang Province, lying between the provincial capital of Hangzhou and the coastal city of Ningbo, in the hinterlands of the Yangtze River Delta economic region. It is well-connected to the transport network, with two sea bridges leading straight to Shanghai, as well as easy access to an airport, the high-speed rail, expressways, national highways, canals and ports. The company's core is in pharmaceutical manufacturing technology and it is engaged in the R&D, production, and operation for pharmaceutical and veterinary APIs and is a well-established manufacturer of synthetic APIs in China. The company's primary products are quinolones and macrolides and it is the world's leading producer of azithromycin, clarithromycin, roxithromycin, ciprofloxacin, enrofloxacin and marbofloxacin. Its production capacity and market share are above 35% in both the Chinese and international markets and its products are exported to 112 countries and regions, covering 6.5 billion people. Its sales network covers all regions of China and the US and European markets. The company is a national high-tech enterprise, with a national-level postdoctoral research station, a province-level pharmaceutical research institute, and a province-level enterprise technology center. It has received National Production Safety Standardization Certification, ISO 9001:2008 quality management certification and ISO 14001 environmental management system certification. All products have received national pharmaceutical and veterinary GMP certification, and all main products have received EUGMP, FDA, PMDA, ANVISA, MFDS and other certifications.